Target Late AMD
Our two first projects were designed to treat rather early stages of AMD before cell loss has been occurred. This third project aims at treating advanced stages of AMD. The approach has been funded by the Fondation de bienfaisance Pierre & Andrée Haas and is entitled “non-viral stem cell-based gene therapy to treat late stages of dry AMD (“Thérapie génique non-virale basée sur les cellules souches pour traiter de la DMLA sèche avancée”). The purpose of the project is to develop a stem cell-based gene therapy product to recover a healthy retinal environment, to replace lost retinal pigment epithelial cells, and to halt photoreceptor cell loss.